How to Better Establish Clinical Utility for Tests in Personalized Medicine
Gary Palmer, MD
Video Categories: Personalized Medicine
Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.
How Oncologists and Pathologists Can Best Collaborate to Provide Precision Medicine for their Patients
Dr David Spigel discusses how medical oncologists and the rest of the cancer care team can best communicate with pathologists to help make informed treatment decisions for individual patients and set up new assays for emerging biomarkers as they are discovered.